Most of the cannabis research we’ve covered on this blog involves oral or inhaled cannabinoids. A newly published pilot study takes a different route entirely — a CBD-based enema — and targets a specific, difficult-to-treat condition: ulcerative proctitis, a form of inflammatory bowel disease affecting the rectum. It’s a good opportunity to walk through how to read an early-stage clinical study properly: what it actually shows, and just as importantly, what it doesn’t.
The Condition and the Approach
Ulcerative proctitis is a localized form of ulcerative colitis, confined to the rectum, causing symptoms like rectal bleeding, pain, and frequent, urgent bowel movements. Standard first-line treatment is mesalamine, an anti-inflammatory medication, but a meaningful subset of patients don’t respond adequately to it — this study specifically enrolled that harder-to-treat population.
The formulation tested, called IcBD-01, combined synthetic CBD with sodium propionate in a daily enema, designed specifically to act locally in the rectum while limiting how much of the compound enters the broader bloodstream. This localized-delivery approach is itself worth noting: much of the cannabinoid research we’ve discussed previously involves systemic exposure through inhalation or oral ingestion, so a topical, localized delivery method aimed at a specific inflamed tissue represents a genuinely different therapeutic strategy.
What the Study Found
The trial, conducted by researchers at Meir Medical Center and Tel Aviv University in Israel, enrolled 14 adults with mild to moderate ulcerative proctitis who had already failed at least three months of mesalamine treatment. Participants self-administered the enema daily for 12 weeks.
The results, among the nine participants who completed the full study, were substantial on paper: the average Mayo score — a standard measure of ulcerative colitis disease activity — dropped from 6.8 to 3.0, a statistically significant reduction. Just over half of study completers reached what researchers classified as clinical remission. Average pain scores fell from 3.8 to 1.2, and endoscopic examination found the average length of ulcerated bowel tissue shrank from 16.4 to 11.7 centimeters, with three participants showing either complete healing of the intestinal lining or only minimal residual inflammation. The treatment was also generally well tolerated, with only two of eighteen reported adverse events considered possibly related to the treatment, and no serious treatment-related events.
Interestingly, not every measure moved in the same direction: the study found no statistically significant improvement in the Nancy histological index or in fecal calprotectin, both objective inflammation markers assessed independently of patient-reported symptoms. That’s a detail worth sitting with rather than skipping past — it suggests the reported symptom improvements didn’t fully align with every biological marker of inflammation, which is exactly the kind of nuance a rigorous, honest study reports rather than smooths over.
Why This Needs a “Pilot Study” Asterisk
This is where a critical read matters most. The study had only 14 participants, nine of whom completed the full protocol — a genuinely small sample by clinical research standards. It was also open-label, meaning both patients and researchers knew they were receiving the active treatment, with no placebo or control group for comparison. The study’s own authors were explicit about this limitation: the design means the results cannot establish that the CBD formulation actually caused the improvements observed, since there’s no way to rule out placebo effect, natural fluctuation in disease activity, or other confounding factors.
There’s one more detail worth being transparent about, in the same spirit of the study’s own authors: the research was funded by CannaMore Biotechs, the company developing the formulation, and one of the study’s authors is an employee of that company. The researchers stated that data collection and analysis were conducted independently — a standard and reasonable safeguard — but funding source is exactly the kind of detail readers deserve to know when weighing how much confidence to place in a result, particularly a small, open-label one like this.
How to Actually Think About This Result
None of this means the study is meaningless — quite the opposite. Pilot studies like this one exist precisely to generate a strong enough signal to justify the far larger investment required for a proper randomized, placebo-controlled trial, which is exactly what the study’s authors say is needed next. A well-tolerated treatment showing meaningful symptom improvement in a patient population that had already failed standard therapy is a genuinely encouraging early result, worth taking seriously as a starting point.
What it isn’t, yet, is proof that CBD enemas treat ulcerative proctitis. That distinction — between “promising early signal” and “established treatment” — is one we’ve returned to repeatedly on this blog, because it’s the single most common place where cannabis research gets overstated in translation from a study abstract to a headline. This particular study, notably, is a good example of research reported responsibly: the original coverage was clear about the sample size, the lack of a control group, and the funding source, which is exactly the kind of transparency that makes early cannabis research trustworthy rather than merely exciting.
Where This Fits
This study adds a useful data point to a theme from our recent post on the broader 2026 research landscape: cannabinoid research is increasingly moving toward specific, targeted delivery methods and mechanisms rather than broad claims about “cannabis” as a single intervention. A localized rectal formulation for a localized bowel condition is a good example of that more precise, mechanism-driven direction — even if, at this stage, it’s a promising first step rather than a conclusion.
Note: the content on this blog is for informational and educational purposes only. It does not replace the advice of a qualified doctor or gastroenterologist. Anyone with inflammatory bowel disease should discuss treatment options, including any experimental or off-label ones, with their treating physician.
WEEDELICIOUS 
Leave a comment